Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empire Prevent: Empagliflozin in elderly obese patients with cardiovascular disease
2020-005317-40Phase 4Completed
- Sponsor
- University Hospital Odense
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of empagliflozin in cardiac morbidity and obesity (2 arms), sponsored by University Hospital Odense. Primary endpoint: Change in peak oxygen consumption (VO2). Started Apr 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
cardiac morbidityobesity
Beyond the preview
Go deeper on 2020-005317-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005317-40.